针对不同背景女性狼疮性肾炎患者的个体化决策辅助工具(IDEA-WON):一项随机对照试验
在美国多中心开放标签随机对照试验中,将301名成年女性狼疮性肾炎患者按1:1随机分配至个体化文化适配计算机决策辅助工具组或美国风湿病学会(ACR)狼疮手册组,分析298人。决策辅助组决策冲突降低有临床意义且统计学显著,知情选择在主分析中无差异,但在敏感性分析中有差异;决策辅助组未解决决策冲突更低,对信息理解度与材料易用性评价更高。
要点
- 决策辅助组决策冲突降低21.8(SE 2.5)vs 手册组12.7(SE 2.0),p=0.005
- 知情选择主分析无差异41% vs 31%(p=0.08),敏感性分析有差异50% vs 35%(p=0.006)
- 未解决决策冲突决策辅助组22% vs 手册组44%(p<0.001)
核心结论
- 个体化决策辅助工具在降低狼疮性肾炎女性选择免疫抑制药物时的决策冲突方面比常规护理更有效。
研究设计与样本
- 美国多中心、开放标签、随机对照试验,纳入在门诊或住院环境中就诊的成年女性狼疮性肾炎患者,多为少数族裔背景且社会经济地位较低。
- 采用计算机生成的随机化,按1:1比例随机分配至个体化文化适配计算机决策辅助工具组或美国风湿病学会(ACR)狼疮手册组。
- 共随机301名女性,分析298名;47%为非裔美国人,26%为西班牙裔,15%为白人;平均年龄(标准差)37(12)岁,57%年收入低于4万美元,36%高中及以下教育。
主要发现
- 决策辅助组(n=151)与ACR狼疮手册组(n=147)相比,决策冲突降低有临床意义且统计学显著:21.8(标准误2.5)vs 12.7(标准误2.0),p=0.005。
- 知情选择主分析无差异:41% vs 31%(p=0.08);敏感性分析(免疫抑制剂的净值正面[支持] vs 负面[反对])有临床意义且统计学显著差异:50% vs 35%(p=0.006)。
- 未解决决策冲突决策辅助组低于手册组:22% vs 44%(p<0.001)。
- 决策辅助组 vs 手册组中,认为信息对理解狼疮性肾炎(49% vs 33%)、风险因素(43% vs 27%)、药物选择(50% vs 33%)为优秀的患者显著更多(所有p≤0.003);材料易用性评价更高(51% vs 38%,p=0.006)。
局限性
- 排除男性。
- 随访时间短。
- 缺乏临床结局,包括药物依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment decision-making regarding immunosuppressive therapy is challenging for individuals with lupus. We assessed the effectiveness of a decision aid for immunosuppressive therapy in lupus nephritis. METHODS AND FINDINGS: In a United States multicenter, open-label, randomized controlled trial (RCT), adult women with lupus nephritis, mostly from racial/ethnic minority backgrounds with low socioeconomic status (SES), seen in in- or outpatient settings, were randomized to an individualized, culturally tailored, computerized decision aid versus American College of Rheumatology (ACR) lupus pamphlet (1:1 ratio), using computer-generated randomization. We hypothesized that the co-primary outcomes of decisional conflict and informed choice regarding immunosuppressive medications would improve more in the decision aid group. Of 301 randomized women, 298 were analyzed; 47% were African-American, 26% Hispanic, and 15% white. Mean age (standard deviation [SD]) was 37 (12) years, 57% had annual income of <$40,000, and 36% had a high school education or less. Compared with the provision of the ACR lupus pamphlet (n = 147), participants randomized to the decision aid (n = 151) had (1) a clinically meaningful and statistically significant reduction in decisional conflict, 21.8 (standard error [SE], 2.5) versus 12.7 (SE, 2.0; p = 0.005) and (2) no difference in informed choice in the main analysis, 41% versus 31% (p = 0.08), but clinically meaningful and statistically significant difference in sensitivity analysis (net values for immunosuppressives positive [in favor] versus negative [against]), 50% versus 35% (p = 0.006). Unresolved decisional conflict was lower in the decision aid versus pamphlet groups, 22% versus 44% (p < 0.001). Significantly more patients in the decision aid versus pamphlet group rated information to be excellent for understanding lupus nephritis (49% versus 33%), risk factors (43% versus 27%), medication options (50% versus 33%; p ≤ 0.003 for all); and the ease of use of materials was higher in the decision aid versus pamphlet groups (51% versus 38%; p = 0.006). Key study limitations were the exclusion of men, short follow-up, and the lack of clinical outcomes, including medication adherence. CONCLUSIONS: An individualized decision aid was more effective than usual care in reducing decisional conflict for choice of immunosuppressive medications in women with lupus nephritis. TRIAL REGISTRATION: Clinicaltrials.gov, NCT02319525.
引用
- Singh JA, Fraenkel L, Green C, et al. Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial. PLoS Med. 2019. PMID: 31067237. doi:10.1371/journal.pmed.1002800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。